Andere Sprachen Takeda Pharmaceutical Company Limited

Aktien

853849

JP3463000004

4502

Markt geschlossen - Japan Exchange Andere Börsenplätze 08:00:00 26.04.2024			% 5 Tage	% 1. Jan.
4.089 ^JPY	-0,02 %		+0,49 %	+0,86 %

26.04.	Hutchmed nimmt die positive Stellungnahme des CHMP für die Zulassung von Fruiquintinib zur Kenntnis	AN
26.04.	Ausschuss der Europäischen Arzneimittelagentur befürwortet Zulassung von Fruquintinib von Takeda zur Behandlung von Darmkrebs	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug	26.04.
Hutchmed notes CHMP's positive opinion for fruiquintinib approval	26.04.
European Medicines Agency Committee Backs Approval of Takeda's Fruquintinib to Treat Colorectal Cancer	26.04.
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer	26.04.
Takeda Receives Positive Chmp Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer	26.04.
Takeda investit cinq millions dans le renouvelable à Neuchâtel	23.04.
Takeda Teams Up With Astellas Pharma, Sumitomo Mitsui Banking to Support Incubation of Early Drug Discovery Programs	22.04.
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs	22.04.
Takeda Pharmaceutical Wins US FDA Approval for Subcutaneous Administration of Crohn’s Disease Therapy	22.04.
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO for Maintenance Therapy in Moderately to Severely Active Crohn's Disease	19.04.
Takeda to Hold Fiscal Year 2023 Earnings Call on May 9	19.04.
Sector Update: Health Care Stocks Steady Pre-Bell Friday	19.04.
Takeda Pharmaceutical Receives FDA Approval for Single-Dose Injection Crohn's Disease Treatment	19.04.
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease	19.04.
U.S. Food and Drug Administration Approves Subcutaneous Administration of Takeda Pharmaceutical Company Limited's ENTYVIO (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease	19.04.
Takeda Says FDA Has Approved Subcutaneous Entyvio for Crohn's Disease	18.04.
Takeda Pharmaceutical to Issue 2nd Hybrid Bonds in Mid-2024 to Refinance 500 Billion Yen 1st Hybrid Bonds	16.04.
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food	08.04.
Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited.	01.04.
Takeda Announces Approval of ADZYNMA Intravenous Injection 1500 in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura	27.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Takeda Pharmaceutical Company Limited

Aktien

853849

JP3463000004

4502

Andere Sprachen

Filter